190-OR: Faster Recovery from Hyperglycemia with Ultrarapid Lispro (URLi) vs. Humalog in Patients with Type 1 Diabetes (T1D) on Continuous Subcutaneous Insulin Infusion (CSII)

Abstract

URLi is a novel insulin lispro formulation developed to more closely match physiological insulin secretion. This randomized, double-blind, 2-period, crossover study compared pharmacokinetics and glucodynamics of URLi vs. Humalog during recovery from hyperglycemia (plasma glucose [PG] >240 mg/dL) due to missed meal bolus or basal insulin suspension in 32 adults with T1D on CSII. Following a missed meal bolus, a correction dose of URLi reduced maximum PG (-13 mg/dL; p=0.02), produced more rapid decline in PG (23 mg/dL/hr; p=0.07), and achieved recovery (PG 140 mg/dL) 23 min earlier (p=0.1) vs. Humalog. Similar results were observed during recovery of hyperglycemia due to basal suspension: a correction dose of URLi reduced maximum PG (-6 mg/dL; p=0.02), produced faster PG decline (24 mg/dL/hr; p The early 50% tmax for insulin lispro occurred sooner (-6 or -12 min; p During episodes of hyperglycemia commonly experienced by patients with T1D, a correction dose of URLi provided faster recovery vs. Humalog, reflective of the faster insulin absorption. Disclosure J. Leohr: None. E. S. Labell: Employee; Self; Eli Lilly and Company, Stock/Shareholder; Self; Eli Lilly and Company, Johnson & Johnson, Novartis AG, Procter & Gamble Company. M. A. Dellva: Employee; Self; Eli Lilly and Company. Z. Tong: Employee; Self; Lilly Diabetes. J. Arrubla: None. L. Plum-moerschel: None. E. Zijlstra: Speaker’s Bureau; Self; Novo Nordisk A/S. T. Fukuda: Employee; Self; Eli Lilly and Company. T. Hardy: Employee; Self; Eli Lilly and Company. Funding Eli Lilly and Company